Otranto Domenico, Paradies Paola, Testini Gabriella, Latrofa Maria Stefania, Weigl Stefania, Cantacessi Cinzia, Mencke Norbert, de Caprariis Donato, Parisi Antonio, Capelli Gioia, Stanneck Dorothee
Department of Veterinary Public Health, Faculty of Veterinary Medicine, University of Bari, Valenzano, Bari, Italy.
Vet Parasitol. 2008 May 31;153(3-4):320-8. doi: 10.1016/j.vetpar.2008.02.008. Epub 2008 Feb 16.
Canine monocytic ehrlichiosis (CME) caused by Ehrlichia canis is the most known canine tick-borne disease (TBD) spread throughout the world. Preventing tick bites is a priority to reduce the risk of TBDs and it was the aim of the present study to evaluate the efficacy of a combination of imidacloprid 10% and permethrin 50% (ImPer) (Advantix; Bayer AG, Germany) in a spot-on formulation to control CME under field conditions. On January-March 2005, 845 dogs from two kennels in southern Italy (kennels of Bari (KB)- and Ginosa (KG)), with a history of tick infestation were initially tested by serology and PCR assay for E. canis infection. Data on Leishmania infantum infection were also available from a previous study carried out on the same dog population. One hundred twenty-six dogs (14.9%) presented anti-E. canis antibodies with a relative prevalence of 15.6% (n=65 dogs in KB) and 14.2% (n=61 dogs in KG). Five hundred thirty-five animals found negative both for E. canis and L. infantum infections were enrolled in three groups (Group A--treated with ImPer once a month; Group B--treated every 2 weeks; and Group C--untreated control animals) and monitored for E. canis infection by serology and PCR in November 2005 (first follow-up) and in March 2006 (second follow-up). The E. canis infection was serologically revealed, at the first and/or second follow-up, in 26 animals from Group C in KB and KG (mean incidence density rate (IDR), 13.24%) while in none of the animals from Group A (KB and KG) and only in one animal from Group B (IDR 1.13%) in KG. The final protection efficacy of ImPer ranged from 95.57% to 100% in Groups B and A. At PCR only 15 dogs from KG were positive for Rickettsiales only at the first follow-up and at the sequence analysis two (both in Group C) revealed 100% homology with E. canis sequences while 13 with Anaplasma platys. Four out of 13 A. platys PCR-positive dogs were also seropositive for E. canis at one or both follow-ups. ImPer, by virtue of its repellent and acaricidal activity against ticks, has been shown to be efficacious to prevent E. canis infection in treated dogs living under natural conditions in endemic areas.
由犬埃立克体引起的犬单核细胞埃立克体病(CME)是世界范围内最广为人知的犬蜱传播疾病(TBD)。预防蜱叮咬是降低蜱传播疾病风险的首要任务,本研究的目的是评估10%吡虫啉和50%氯菊酯组合(ImPer)(Advantix;德国拜耳公司)的滴剂制剂在野外条件下控制CME的效果。2005年1月至3月,对意大利南部两个犬舍(巴里犬舍(KB)和吉诺萨犬舍(KG))的845只曾有蜱虫寄生史的犬只,最初通过血清学和PCR检测犬埃立克体感染情况。关于婴儿利什曼原虫感染的数据也可从之前对同一犬群进行的研究中获得。126只犬(14.9%)呈现抗犬埃立克体抗体,在KB犬舍相对患病率为15.6%(n = 65只犬),在KG犬舍为14.2%(n = 61只犬)。535只犬对犬埃立克体和婴儿利什曼原虫感染检测均为阴性,被分为三组(A组——每月用ImPer治疗一次;B组——每2周治疗一次;C组——未治疗的对照动物),并于2005年11月(首次随访)和2006年3月(第二次随访)通过血清学和PCR监测犬埃立克体感染情况。在首次和/或第二次随访时,通过血清学检测发现,KB和KG犬舍C组的26只犬感染了犬埃立克体(平均发病密度率(IDR)为13.24%),而A组(KB和KG)的犬只均未感染,KG犬舍B组仅1只犬感染(IDR为1.13%)。ImPer在B组和A组的最终保护效果为95.57%至100%。在PCR检测中,仅KG犬舍有15只犬在首次随访时仅对立克次氏体呈阳性,序列分析显示其中2只(均在C组)与犬埃立克体序列有100%同源性,13只与血小板无形体同源。13只血小板无形体PCR阳性犬中有4只在一次或两次随访时对犬埃立克体血清学检测也呈阳性。ImPer凭借其对蜱的驱避和杀螨活性,已被证明对预防流行地区自然环境下生活的犬只感染犬埃立克体有效。